Christopher A Burnett

Title: Christopher A. Burnett: Innovator in Integrin Receptor Antagonists

Introduction

Christopher A. Burnett is a notable inventor based in College Park, MD (US). He has made significant contributions to the field of medical imaging and therapy through his innovative work on integrin receptor antagonists. His research focuses on enhancing the binding affinity of these antagonists, which has important implications for therapeutic applications.

Latest Patents

Burnett holds a patent titled "Integrin α-v β-3 antagonists for use in imaging and therapy." This patent describes integrin receptor antagonists whose molecular structure includes a tetrahydropyridimidinylaminoethyloxybenzoyl group on a sulfonylamino-β-alanine nucleus. These compounds exhibit increased binding affinity for the αvβ3 receptor when further modified with specific groups, such as an N-amino alkycarbamyl group or a butyloxycarbonylamino alkylcarbamoyl group.

Career Highlights

Burnett's career is marked by his dedication to advancing medical research and developing innovative solutions for complex health challenges. He works for the United States of America, as represented by the Secretary, Department of Health and Human Services. His work has led to advancements in the understanding and application of integrin receptor antagonists.

Collaborations

Throughout his career, Burnett has collaborated with esteemed colleagues, including King Chuen Li and S. Narasimhan Danthi. These collaborations have fostered a productive research environment, leading to significant advancements in their field.

Conclusion

Christopher A. Burnett is a distinguished inventor whose work on integrin receptor antagonists has the potential to transform medical imaging and therapy. His innovative approach and dedication to research continue to make a lasting impact in the field.